Literature DB >> 1374791

Sequence analysis of an HIV-1 isolate which displays unusually high-level AZT resistance in vitro.

M Muckenthaler1, N Gunkel, P Levantis, K Broadhurst, B Goh, B Colvin, G Forster, G G Jackson, J S Oxford.   

Abstract

Multiple mutations in the reverse transcriptase (RT) gene were observed in a drug-resistant isolate of human immunodeficiency virus type 1 (HIV1) from an individual having prolonged (greater than 2 years) zidovudine (AZT) therapy. The virus replicated in PBMC's in the presence of very high concentrations of AZT (125 microM). Drug-sensitive strains were curtailed by 0.01 microM AZT. Eleven defined mutations were observed as compared with published sequences of RT for eight strains of HIV1. Eight of these mutations were found in the domain involved in nucleotide recognition and enzyme function. Only one of the mutations, giving a Thr--Tyr change at amino acid 215, matched those previously ascribed (67, 70, 215, and 219) to the generation of high-level resistance to AZT. Therefore additional amino acid changes may have significance in the emergence of super-resistant viruses.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1374791     DOI: 10.1002/jmv.1890360204

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  Antiviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions.

Authors:  R F Schinazi; R M Lloyd; C S Ramanathan; E W Taylor
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

2.  An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.

Authors:  D J Hooker; G Tachedjian; A E Solomon; A D Gurusinghe; S Land; C Birch; J L Anderson; B M Roy; E Arnold; N J Deacon
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 3.  Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents.

Authors:  D D Richman
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

4.  Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: longitudinal evaluation of six patients under treatment.

Authors:  M Zazzi; M Catucci; A De Milito; L Romano; G Venturi; P Almi; A Gonnelli; M Rubino; P E Valensin
Journal:  Infection       Date:  1996 Nov-Dec       Impact factor: 3.553

5.  Inhibition of human immunodeficiency virus type 1 integrase by 3'-azido-3'-deoxythymidylate.

Authors:  A Mazumder; D Cooney; R Agbaria; M Gupta; Y Pommier
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.